This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to ...

Growth of five distinct patient-derived organoid models was dose-dependently inhibited by CDDD11-8 (IC50 range: 272-771 nM), including three derived from MYC amplified, chemo-resistant TNBC ...